MULTIPLE MYELOMA (MM), LYMPHOMA, LARGE B-CELL, DIFFUSE (DLBCL), LYMPHOMA
Clinical trials for MULTIPLE MYELOMA (MM), LYMPHOMA, LARGE B-CELL, DIFFUSE (DLBCL), LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new MULTIPLE MYELOMA (MM), LYMPHOMA, LARGE B-CELL, DIFFUSE (DLBCL), LYMPHOMA trials appear
Sign up with your email to follow new studies for MULTIPLE MYELOMA (MM), LYMPHOMA, LARGE B-CELL, DIFFUSE (DLBCL), LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Engineered donor cells take aim at Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new approach using immune cells from healthy donors, engineered to recognize and attack cancer cells. The target is chosen based on each participant's tumor profile. The trial includes 85 adults with advanced solid tumors that have not responded to standard tre…
Matched conditions: MULTIPLE MYELOMA (MM), LYMPHOMA, LARGE B-CELL, DIFFUSE (DLBCL), LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Essen Biotech • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
Pill vs. needle: can Lower-Dose blood thinners protect blood cancer patients from deadly clots?
Disease control Recruiting nowThis study compares two types of blood thinners taken as pills (apixaban and rivaroxaban) against a standard daily injection (enoxaparin) to prevent dangerous blood clots in people with blood cancers like lymphoma, leukemia, and multiple myeloma. About 100 participants will be ra…
Matched conditions: MULTIPLE MYELOMA (MM), LYMPHOMA, LARGE B-CELL, DIFFUSE (DLBCL), LYMPHOMA
Phase: NA • Sponsor: Medical University of Gdansk • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
Simple test may predict who can handle tough cancer therapy
Knowledge-focused Recruiting nowThis study is testing whether a quick, practical geriatric assessment—looking at mobility, memory, self-care, and nutrition—can predict severe side effects in patients 65 and older who are about to receive CAR-T cell or bispecific antibody therapy for blood cancers like multiple …
Matched conditions: MULTIPLE MYELOMA (MM), LYMPHOMA, LARGE B-CELL, DIFFUSE (DLBCL), LYMPHOMA
Sponsor: University of Zurich • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:07 UTC
-
AI robot teaches patients about clinical trials – will it boost participation?
Knowledge-focused Recruiting nowThis study tests whether an AI-powered chatbot can help people with blood cancers like leukemia and lymphoma better understand clinical trials and feel more willing to join them. Researchers will compare patients who get standard education plus AI chatbot sessions to those who on…
Matched conditions: MULTIPLE MYELOMA (MM), LYMPHOMA, LARGE B-CELL, DIFFUSE (DLBCL), LYMPHOMA
Phase: NA • Sponsor: Zhongnan Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:06 UTC